Strengthening regulatory systems for medicines in a changed world
Where do we go from here
Bibliographic Data
| ID | 21879949 |
|---|---|
| Authors | Julie O'Brien (0000-0001-9301-461X, Pfizer (Ireland), corresponding author), Rebecca Lumsden (0000-0001-8737-0191, Pfizer (United Kingdom)), Judith Macdonald (0000-0001-8098-6612, Pfizer (United Kingdom)) |
| Year | 2021 |
| Volume | 6 |
| Issue | 1 |
| Pages | e004680 |
| Publication date | 2021-01-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | BMJ Global Health (JOURNAL) |
| Journal identifiers | ISSN: 2059-7908 • E-ISSN: 2059-7908 |
| Publisher | BMJ (PUBLISHER • GB) |
| DOI | 10.1136/bmjgh-2020-004680 |
| PMID | 33495287 |
| OpenAlex | W3124651309 |
| Language | EN |
| Citations received | 1 |
| References cited | 5 |
Strengthening regulatory systems for medicines in low-income and middle-income countries is critical to ensure fit for purpose, future-proofed and efficient regulatory systems that facilitate access to safe and effective medicines for patients; this holds true before, during and after the COVID-19 pandemic
Benchmarking · Business · Globe · Political science · Regulatory authority · Biomedical Ethics and Regulation · Computer Science · Health Systems, Economic Evaluations, Quality of Life · Medicine · Pharmaceutical Economics and Policy · Public Administration · Marketing
| Citations per year | 0.25 |
|---|---|
| Citation span | 2022 - 2022 (1) |
| Highly cited | No |